Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PAM | P19021 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28190668 | 0.98 | THRB (0.49) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL28190619 | 0.98 | THRB (0.49) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL195300 | 0.96 | THRB (0.50) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL18828850 | 0.95 | DGKA (0.52) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL28189937 | 0.95 | THRB (0.49) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL18828851 | 0.95 | DGKA (0.52) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL28189941 | 0.95 | DGKA (0.52) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL18829035 | 0.95 | DGKA (0.52) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL14183092 | 0.95 | TSHR (0.51) | THRBTSHRPOLBAPEX1HTT | |
| Ammonia Solution, Strong SCHEMBL28189965 | 0.93 | TSHR (0.50) | THRBTSHRPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | L'OREAL (FR) | 2018-06-26 | — | — | US | claimed |
| EP-0462670-B1 | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same | JOHNSON & JOHNSON CLIN DIAG (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0462644-B1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | JOHNSON & JOHNSON CLIN DIAG (US) | 1995-10-18 | — | — | EP | claimed |
| EP-0325038-B1 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PROD INC (US) | 1993-11-03 | — | — | EP | claimed |
| US-5155166-A | Diagnostic kits for detecting antibodies or antigens; reacting active amine- or sulfhydryl-containing compound with quaternized carboxylic polymers | EASTMAN KODAK COMPANY (US) | 1992-10-13 | — | — | US | claimed |
| US-5147777-A | Analysis, diagnosis | EASTMAN KODAK COMPANY (US) | 1992-09-15 | — | — | US | claimed |
| EP-0462670-A1 | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to caboxylated particles & a kit containing same | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | claimed |
| EP-0462644-A1 | Biologically active reagents prepared from carboxy-containing polymer, analytical element and methods of use | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1991-12-27 | — | — | EP | claimed |
| US-4913939-A | Reaction product of cyclic anhydride and hydroxy compound; adhesion of adhesives | REM SYSTEMS, INC. (US) | 1990-04-03 | — | — | US | claimed |
| US-4863993-A | Surface priming composition for proteinaceous substrates; method of making and using same | OPI PRODUCTS, INC. (US) | 1989-09-05 | — | — | US | claimed |
| EP-0325038-A2 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PRODUCTS, INC. (US) | 1989-07-26 | — | — | EP | claimed |
| CN-115710277-A | Ethylene glycol unit-containing alkenyl-terminated tetraaryl porphyrin compound and preparation method and application thereof | 江苏海伦隐形眼镜有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220120649-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-11237085-B2 | Ligand-functionalized substrates with enhanced binding capacity | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3052556-B1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | 3M INNOVATIVE PROPERTIES CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-4883734-A | Toner for development of electrostatic image and method of fixing employing the same | KONICA CORPORATION (JP) | 1989-11-28 | — | — | US | disclosed |
| US-4882258-A | Toner for development of electrostatic image and electrostatic latent image developer | KONICA CORPORATION (JP) | 1989-11-21 | — | — | US | disclosed |
| US-4863993-A | Surface priming composition for proteinaceous substrates; method of making and using same | OPI PRODUCTS, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0325038-A2 | Surface priming composition for proteinaceous substrates, method of making and using same | OPI PRODUCTS, INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4618557-A | Liquid developer for electrostatic photography | FUJI PHOTO FILM CO., LTD. (JP) | 1986-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11237085-B2 | Ligand-functionalized substrates with enhanced binding capacity | ILK, EPCAM, ECPAS | THRB 2283/4885TSHR 3878/4885POLB 3741/4885 |
| US-20220120649-A1 | LIGAND-FUNCTIONALIZED SUBSTRATES WITH ENHANCED BINDING CAPACITY | ILK, EPCAM, ECPAS | THRB 2283/4885TSHR 3878/4885POLB 3741/4885 |
| US-10004673-B1 | Hair treatment composition comprising Michael addition product and methods for treating hair | SRM, CRAT, C9 | THRB 1763/4885TSHR 1844/4885POLB 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.